BioCentury | Oct 20, 2017
Clinical News
Aerie's Rhopressa wins FDA panel votes
...discontinuation rate due to adverse events -- 19.3% for Rhopressa compared with 1.7% for comparator timolol...
...patients in pooled data from four Phase III trials compared with less than 1% of timolol...
...Rhopressa lowers IOP, but noted that clinical data showed the therapy was less efficacious than timolol...
...patients in pooled data from four Phase III trials compared with less than 1% of timolol...
...Rhopressa lowers IOP, but noted that clinical data showed the therapy was less efficacious than timolol...